What are the current Society for Maternal-Fetal Medicine (SMFM) and American College of Obstetricians and Gynecologists (ACOG) recommendations for vaginal progesterone use in a 15‑week pregnant patient with a history of two prior 28‑week preterm labor deliveries?

SMFM and ACOG Recommendations for Vaginal Progesterone in This Patient

Based on current SMFM and ACOG guidelines, this patient with two prior spontaneous preterm births at 28 weeks should receive 17-alpha hydroxyprogesterone caproate (17P) 250 mg intramuscularly weekly starting now at 15 weeks until 36 weeks—NOT vaginal progesterone. However, given the FDA withdrawal of 17P in April 2023, the current recommendation is to NOT use progesterone supplementation at this time unless cervical length shortening is documented.

The Evidence-Based Algorithm

For Patients with Prior Spontaneous Preterm Birth:

Primary recommendation (pre-2023):

• 17P 250 mg IM weekly from 16-20 weeks until 36 weeks was the standard of care 1

Current recommendation (post-FDA withdrawal 2023):

• 17P is no longer available or recommended 2
• Vaginal progesterone is NOT recommended for patients with prior spontaneous preterm birth and normal/unknown cervical length 1, 3

The Critical Distinction: Cervical Length Matters

The key to progesterone use in this patient is cervical length assessment:

If cervical length ≥25 mm or unknown:

• Continue 17P if already started (though now withdrawn)
• Do NOT initiate vaginal progesterone 1, 3
• Perform serial transvaginal ultrasound cervical length screening 1

If cervical length shortens to <25 mm before 24 weeks:

• Consider adding vaginal progesterone 90-mg gel or 200-mg suppository daily until 36 weeks 1
• Continue 17P if already on it (though evidence for dual therapy is limited) 1
• Consider cerclage if cervix <15 mm 1

Why Vaginal Progesterone Alone Is NOT Recommended

The 2017 SMFM statement explicitly addressed this question 3:

• Multiple large randomized controlled trials (including the OPPTIMUM study with 903 women with prior spontaneous preterm birth) showed no significant reduction in preterm birth <34 weeks with vaginal progesterone versus placebo (15.9% vs 18.8%) 3
• Vaginal progesterone has NOT been adequately proven to decrease recurrent preterm birth in women with prior spontaneous preterm birth 3
• SMFM reaffirms that 17P (now withdrawn) was the recommended agent, NOT vaginal progesterone 3

The 2024 SMFM Update on Short Cervix

The most recent 2024 SMFM guideline 4 clarifies that vaginal progesterone is recommended for:

• Patients WITHOUT prior spontaneous preterm birth who develop a short cervix (≤20 mm) before 24 weeks (GRADE 1A)
• Consideration at cervical length 21-25 mm based on shared decision-making (GRADE 1B)

This guideline specifically recommends AGAINST 17P for short cervix treatment 4, but does not change the historical recommendation that patients with prior spontaneous preterm birth should receive 17P (not vaginal progesterone) as primary prevention.

Current Clinical Approach Post-FDA Withdrawal

Following the April 2023 FDA withdrawal of 17P 2:

For your patient at 15 weeks with two prior 28-week deliveries:

1. Do NOT prescribe vaginal progesterone routinely based on history alone
2. Perform transvaginal cervical length screening starting at 16-24 weeks 1, 4
3. If cervical length ≤20 mm is detected:
   • Prescribe vaginal progesterone 90-mg gel or 200-mg suppository daily until 36 weeks 4
   • This is a GRADE 1A recommendation for short cervix regardless of prior preterm birth history 4
4. If cervical length 21-25 mm:
   • Consider vaginal progesterone through shared decision-making 4
5. If cervical length ≥25 mm:
   • No progesterone supplementation is recommended
   • Continue serial cervical length monitoring

Important Caveats

The evidence gap: The 2012 SMFM algorithm 1 showed that in women with prior spontaneous preterm birth who developed cervical shortening <25 mm while on 17P, there was insufficient evidence to assess efficacy of switching to vaginal progesterone, and recommended continuing 17P 1. This suggests that even with cervical shortening, vaginal progesterone's benefit in this population was uncertain.

Shared decision-making consideration: Given that this patient previously received progesterone in prior pregnancies (implied by the question), SMFM's 2023 statement 2 suggests that discussion of vaginal progesterone for primary prevention may include shared decision-making, especially if progesterone was used previously. However, this is not a strong recommendation.

The bottom line: Without documented cervical shortening, vaginal progesterone is not indicated based on history alone, even with two prior preterm births at 28 weeks.